

FIG. 1b




FIG. 1d




FIG. 1a




FIG. 1c

**BOLUS INJECTIONS OF 0.1 $\mu\text{mol/kg}$ S-NO-HSA +
GSH ($\mu\text{mol/kg}$) – *in vivo***




FIG. 1e




FIG. 1f

Potentiation of the NO-release of S-NO-HSA (30 $\mu\text{mol/L}$) by GSH

(in vitro, n=6, * $P<0.05$ vs S-NO-HSA; # $P<0.05$ vs GSH 25 $\mu\text{mol/L}$)




FIG. 2a

Potential of the NO-release of S-NO-HSA by GSH

(In vitro; phsiol. NaCl, pH=6.5)




FIG. 2b

Dose-dependent potentiation of the inhibition of the collagen-induced platelet aggregation by S-NO-HSA (2 - 4 $\mu\text{mol/L}$) with reduced glutathione




FIG. 3a

Effect of N-acetyl cysteine (1 mmol/L), ascorbic acid (Vit.C; 200 μ mol/L), reduced glutathione, homocysteine, taurine and cysteine (1 mmol/L in each case) on the inhibition of the collagen-induced platelet aggregation by S-NO-HSA (2 - 4 μ mol/L)




FIG. 3b




FIG. 4a

FIG. 4b

FIG. 4c